Table 2.

Association of detectable urinary properdin and detectable urinary sC5b-9 with graft failure in renal transplant recipients.

Model	Detectable properdin		Detectable sC5b-9		Both properdin and sC5b-9
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Univariate	3.08 (1.95–4.85)	<0.001	4.17 (2.63–6.63)	<0.001	7.13 (4.30–11.83)	<0.001
Model 1	2.35 (1.44–3.82)	0.001	3.03 (1.86–4.96)	<0.001	8.04 (4.74–13.63)	<0.001
Model 2	2.27 (1.38–3.73)	0.001	2.99 (1.83–4.89)	<0.001	7.63 (4.46–13.10)	<0.001
Model 3	2.30 (1.37–3.82)	<0.001	3.09 (1.87–5.11)	<0.001	6.75 (3.79–12.02)	<0.001
Model 4	1.47 (0.85–2.54)	0.05	2.16 (1.30–3.61)	0.003	3.12 (1.69–5.77)	<0.001

Model 1, adjustment for age, sex, primary renal disease, time since transplantation at inclusion, eGFR, HLA mismatches, and donor type; model 2, model 1 + adjustment for hs-CRP; model 3, model 2 + adjustment for systolic blood pressure, and smoking; model 4, model 3 + adjustment for proteinuria.

Reference group defined as patients with neither urinary properdin or C5b-9, with a hazard ratio of 1.0.